{"relation": [["", "STARTED", "COMPLETED", "NOT COMPLETED", "Investigator's Discretion", "Lost to Follow-up", "Study Site Discontinued", "Withdrew Consent"], ["TDF-TDF", "183", "176", "7", "1", "3", "1", "2"], ["ADV-TDF", "93", "90", "3", "1", "1", "0", "1"]], "pageTitle": "A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00117676?view=record", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 12, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987866.61/warc/CC-MAIN-20150728002307-00043-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 856131850, "recordOffset": 856115456, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Period 1: \u00a0 Double-blind Period Through Week 48 Participant Flow for 8 periods ADV 10 mg plus placebo to match TDF (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added FTC (as part of FTC 200 mg/TDF 300 mg FDC tablet) to their treatment regimen in the open-label period. ADV-TDF Tenofovir disoproxil fumarate (TDF) 300 mg plus placebo to match adefovir dipivoxil (ADV) (double-blind period), followed by TDF 300 mg (open-label period). Participants may have added emtricitabine (FTC; as part of FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet) to their treatment regimen in the open-label period. TDF-TDF Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details There were 79 enrolling sites in 15 countries. The first participant was screened on 07 June 2005, and the last participant was randomized on 15 May 2006. The last participant observation for the primary endpoint analysis (Week 48) was", "textAfterTable": "Period 2: \u00a0 Open-label Period: Weeks 49 - 96 \u00a0 \u00a0 TDF-TDF \u00a0 \u00a0 ADV-TDF \u00a0 STARTED \u00a0 \u00a0 235 [1] \u00a0 112 [1] COMPLETED \u00a0 \u00a0 225 \u00a0 \u00a0 110 \u00a0 NOT COMPLETED \u00a0 \u00a0 10 \u00a0 \u00a0 2 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 Safety, Tolerability, or Efficacy Reason \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 3 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Withdrew Consent \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}